Cellectar Biosciences Inc (NASDAQ:CLRB) shares were up 13% on Thursday . The company traded as high as $1.45 and last traded at $1.39. Approximately 1,061,888 shares changed hands during mid-day trading, an increase of 163% from the average daily volume of 404,508 shares. The stock had previously closed at $1.23.
A number of research analysts recently weighed in on CLRB shares. Zacks Investment Research cut Cellectar Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, November 21st. ValuEngine upgraded Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). sell-side analysts forecast that Cellectar Biosciences Inc will post -0.96 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/23/cellectar-biosciences-clrb-trading-up-13.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.